When hepatitis B vaccine was licensed in the Netherlands in 1982, a program was started to screen mothers for HBsAg positivity and to immunize their offspring. In the first randomized trial a passive-active immunization schedule starting at birth was compared with a schedule with active immunization starting at 3 months of age, concomitant with diphtheria-tetanus-pertussis and pohomyelitis (DTPP) vaccination. The authors hypothesized that efficacy of delayed active immunization would be similar, but long-term immunogenicity superior to immunization starting at birth. Such a result would allow incorporation of active hepatitis B immunization in the standard infant immunization program, which was thought to be advantageous with respect to logistics and costs. Our preliminary results supported this hypothesis','. In 1984 a second randomized trial was started to compare the short-and longterm immunogenicity of the standard vaccine dose with a pediatric dose. With the introduction of recombinant vaccine in 1987, a third randomized trial was performed to confirm the efficacy of delayed vaccination with the recombinant vaccine; this trial also allowed testing the need for supplementary hepatitis B immunoglobulins (HBIg) at the start of delayed active immunization3.
Our recent finding4, also observed by others '-7 , that vaccination failure is also related to high maternal HBV DNA levels made it necessary to re-evaluate the effects of the components of the various schedules: time of starting active immunization, types and doses of vaccine and HBIg used, in relation to maternal HBV DNA levels.
This final report of the Dutch program for prevention of perinatal hepatitis B describes the protective efficacy and long-term immunogenicity of passiveactive hepatitis B immunization over a period of 10 years.
SUBJECTS AND METHODS

Hepatitis B screening
The study was started in July 1982 in three large city hospitals in Rotterdam and Utrecht and one large rural area, Twente-Gelderse Achterhoek.
Blood samples obtained from all pregnant women at their first visit to the prenatal clinic of the participating centers were tested for the presence of HBsAg. If HBsAg positivity was confirmed, randomization to one of the immunization schedules took place after informed consent was Table 1 Immunization schedules of study groups obtained from the mother. In the two participating hospitals in Rotterdam, the HBsAg status of expectant mothers was checked soon after arrival in the delivery room. Whenever prenatal HBsAg test results were missing, blood was obtained and tested the next morning with a rapid hemagglutination HBsAg test. If the rapid HBsAg test was positive, the mother was asked for informed consent and the baby was randomized and included in the immunization trial. All pregnant HBsAg-positive women were also tested for the presence of HBeAg. In December 1992, maternal HBV DNA levels were quantified retrospectively in the available stored serum samples positive for HBeAg.
Subjects and immunization schedules
From July 1982 to March 1984, 238 eligible babies were randomly allocated to one of the two initial plasma vaccine immunization schedules (Tahlu I, groups I-II); from April 1984 to December 1987. 257 babies entered the plasma vaccine immunogenicity study (Table I , groups III-IV); from January 1988 to October 1989, another 210 eligible babies were allocated to one of the two recombinant vaccine immunization schedules (Table I , groups V-VI).
All infants received HBlg (200-300 IU, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam) i.m. within 2 h of birth by the physician or midwife in charge of the delivery. For active immunization, infants were referred to a pediatrician. Infants received plasma vaccine (10 and 5 /cg HBvax, Merck Sharp & Dohme, West Point, USA) or recombinant vaccine (20 /lg Engerix-B, SmithKline Beecham, Rixensart, Belgium). Nine infants (one in group II, three in group III and five in group IV) with an anti-HBs level I 10 IU 1 ' at 12 months of age and a negative test for HBsAg received an additional course of plasma vaccine or recombinant vaccine in their second year of life.
Serological assays and laboratory methods
Blood samples were taken from the infants at birth (cord blood) and in groups I and II at months 3, 6, I I, 12 and then yearly until 9 years of age; in groups III and IV at months 3, 6, 12 and then yearly until 5 years of age; in groups V and VI at months 3. 4, 6, 11, 12 and at 2 years of age. All serum samples were tested for anti-HBs and anti-HBc; HBsAg w$s assayed in all samples with anti-HBs below lot) IU 1 . HBsAg, HBeAg, anti-HBc and anti-HBs were assessed using a commercial radioimmunoassay kit (Abbott Laboratories, Chicago, IL, USA). HBV DNA was measured quantitatively by a solution hybridization assay (HBV DNA, Abbott Laboratories).
Definition of HBV infection
A HBV carrier state was defined as being HBsAg positive for more than 6 months. Transient HBV infection was characterized by the presence of HBsAg in serum for less than 6 months. Inapparent HBV infection was defined as anti-HBc positivity without HBsAg on two or more occasions after 12 months.
Statistical analysis
Available data were analysed according to the intention-to-treat principle. Separate per-protocol analysis, i.e. analysis of data of children who received vaccinations according to protocol, was also performed. The results of these analyses did not differ significantly. Therefore, the authors report on the protective efficacy using outcomes of the intention-to-treat analysis; the results on the immunogenicity are reported using the outcomes of the per-protocol analysis.
For analysis of factors affecting the protective efficacy rate, logistic regression analysis8 was applied. Confidence limits for odds ratio were calculated using the statistical software package 'STATXACT'. Differences in percentages were analysed by xz test or Fisher's exact test in case of small numbers. Continuous variables were analysed by the two-sample Wilcoxon rank-sum test. The limit for significance was set to 0.05 (two-sided). In case of evaluations at various timepoints, the limit of significance was set according to Bonferroni's principle to allow for the multiplicity of statistical tests. Geometric mean titers (GMT) were calculated only for those infants who had anti-HBs 2101u1-'.
Ethics
The study was approved by the local Medical Ethics Committee of the participating centers.
RESULTS
Follow-up
From July 1982 until October 1989, 705 infants of HBsAg-positive mothers were randomized into three controlled trials. Sixteen infants were withdrawn after informed consent but before vaccination, 12 infants received at least one vaccination, but no serum sample was available after month 0. In total, 677 infants received full courses of passive-active immunization according to six schedules (Table I) . Thirteen infants received vaccinations but not according to protocol (one in group I, four in group II, one in group III, one in group IV, three in group V and three in group VI). Thus, 664 infants received passive-active immunization according to protocol. Serum samples were available from 590 children at 1 year of follow-up, 546 after 2 years, 262 after 5 years and 126 after 8 years. Incomplete data from these children were primarily due to
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Protective efficacy of perinatal HBV immunization
At month 12, HBsAg positivity was found in tight of 590 infants. Of 33 infants no strum sample was available at month 12 but they wcrc HBsAg ncgativc thcrcafter, so the assumption was made that thcrc was no HBsAg positivity at month 12. From tight of the I3 infants who received a vaccination schcdulc not according to protocol, strum samples wcrc availahlc and found to bc HBsAg ncgativc at month 12 or thcrcafter. Of 631 (i.e. 590+3+8) infants analyscd, tight (1.3%) were found to be HBsAg-positive during the first year of lift. All HBsAg-positive children wcrc born to HBeAg-positive mothers.
One infant of a HBcAg-ncgativc mother bccamc HBsAg positive at the age of 5 years (&p-c I) ; it had a peak anti-HBs lcvcl bctwccn 10 and IO0 IU I ' after vaccination, but was anti-HBs ncgativc from 2 years onwards. This child and all infants found to bc HBsAgpositive in the first year hccamc hepatitis B carriers.
Inapparcnt HBV infection (anti-HBc positivity with negative HBsAg tests on two or more occasions after month 12) was observed in tight infants, all born to HBeAg-positive mothers.
At month 12, the protcctivc cfticacy rate (PER) of passive-active immunization for the I I4 infants of HBsAg-and HBcAg-positive mothers was YO%. (Table 2) . No significant diffcrcnccs wcrc found between the PER for infants starting active vaccination at birth and those starting at 3 months; bctwccn infants starting at 3 months and rccciving one or two doses of HBIg and hctwcen infants rccciving plasma vaccine or recombinant vaccine.
In 72 of the 114 HBcAg-positive mothers, residual frozen serum was available for quantitative HBV DNA assessment in lY92. Tuhk 3 shows the relation of maternal HBV DNA levels and the number of infants who became HBV carriers. The PER at month 12 for the two groups with HBV DNA lcvcls < I50 pg ml ' were 100% and significantly higher than the PER (68%) for the group with maternal HBV DNA lcvcls 2 150 pg ml ' (P = 0.009). for infants from HBeAg positive mothers is usually estimated at 90%"~", however, PER was also calculated for 67% expected HBV infections without immunoprophylaxis, in view of the finding that one-third of infants of HBeAg-positive mothers had HBV DNA < 5 pg ml ' and are therefore unlikely to transmit hepatitis B to their infants' Figure 2 shows the maternal HBV DNA levels for HBV infected infants and non-infected infants. The median maternal HBV DNA level of the HBV carrier infants and that of the inapparently infected infants were ten times higher ( ~350 pg ml-') than the median maternal HBV DNA level (31 pg ml ') of the infants without HBV infection (P = 0.001 and 0.03, respectively).
When data on time of starting active vaccination, number of doses of HBIg and type of vaccine were analysed by multivariate logistic regression, no significant differences were found (odds ratio confidence intervals were from 0.001 to > 10). When the analysis was expanded with HBV DNA data, both the factor HBV DNA as well as HBV DNA > 150 pg mll' were significantly associated with the PER.
Long-term immunogenicity
Assuming a minimal risk for hepatitis B infection in vaccinees with anti-HBs levels > 10 IU I-', and a potential risk with anti-HBs levels < 10 IU ll', the authors calculated the percentages of infants with antiHBs < 10 IU ll' in the different immunization groups (Figure 3) . At the age of 5 years, the group that started at 3 months of age with plasma vaccine (group II) had a significantly lower percentage (2%, 95% CI O-6%) of children with anti-HBs < 10 IU 1 ' than group I (14%, 95% CI 6-23%) that started immunization at birth (Fisher's exact test, P = 0.02). The percentage of infants with anti-HBs < 10 IU 1. ' in group II never exceeded 5% during the 5 year follow-up, whereas the corresponding percentage in the other immunization groups increased to > 15% during follow-up. Table 4 shows the GMT of anti-HBs (anti-HBs 210 IU I-') in the different immunization groups during follow-up. GMT of group II (10 ,ug plasma vaccine administration from 3 months of age onwards) was approximately double that of group I (starting at birth with 10 lug plasma vaccine). In the groups with different dosages of vaccine, the GMT at month 12 in group III with three doses of 10 pg plasma vaccine administered from birth onwards, was approximately double that of group IV, which received the same schedule but only 5 pg of plasma vaccine. However, this difference was not significant after 36 months of follow-up. Comparison of GMT values of groups given plasma vaccine or recombinant vaccine from 3 months onwards showed that the group receiving plasma vaccine (group II) had an approximately one and half times higher GMT than the corresponding group receiving recombinant vaccine (group VI) (P<O.OOl at all times measured).
DISCUSSION.
In this meta-analysis of individual patient data of three randomized controlled trials, the PER against hepatitis B infection for infants of HBeAg-positive carrier mothers was 90% at 12 months of age; for infants of HBeAg-negative mothers it was 100%. These rates are comparable to those found in other passive-active immunization studies, with either plasma-derived or recombinant vaccine9-'3. During follow-up beyond 1 number of HBsAg-positive infants in group with HBV DNA > 150 pg ml-' and groups with HBV DNA of 7-l 50 and <6 pg ml-'; owing to small numbers of infants, the exact 95% CI of the ratio of the odds of HBsAg positivity in the group of infants with HBV DNA <I 150 pg ml-' (odds O/48) versus the corresponding odds (7/24) in the group with HBV DNA > 150 pg ml-' was calculated (this 95% CI ranged from 0 to 0.22); anot applicable, in view of the finding that infants of HBeAg-positive mothers with HBV DNA <5 pg ml-' are unlikely to transmit hepatitis B to their infants' year, extending to 9 years, one vaccinated infant of an HBeAg-negative mother became positive for HBsAg.
The timing of the initial vaccine injection, the type of the vaccine and the number of doses of HBIg had no effect on the PERs. These results confirm earlier findings. Beasley In the setting of our program, with the use of licensed vaccine and adequate dosage of HBIg, the single clinically relevant factor that did influence the PER was the level of serum HBV DNA of the mother at the time of delivery. PER in groups of infants with maternal HBV DNA levels < 150 pg ml-' was lOO%, but only 68% for the group with a maternal HBV DNA level of 2 150 pg ml-~'.
To verify the finding that PER is markedly influenced by maternal HBV DNA levels, the authors analysed the protective efficacy rate at 12 months of age according to quantified maternal HBV DNA levels from the neonatal hepatitis B vaccination program in Hong Kong (9 P.N. Lelie, written communication). In the Hong Kong study, no persistent HBsAg positivity at 12 months was detected in infants with maternal HBV DNA <5 pg ml-', irrespective of immunization schedule. Infants with maternal HBV DNA between 7 and 150 pg ml-' were at risk of hepatitis B infection (15-28% HBsAg carrier rate). Infants with maternal HBV DNA levels of > 150 pg ml-' were at high risk of hepatitis B; 25-50% of infants became persistent HBsAg positive despite immunization. These results strongly support the concept that the level of maternal HBV DNA is the major factor influencing the PER of hepatitis B immunization.
Recently, hepatitis B 'escape mutants', lacking the 'a' epitope on the viral envelope were found in vaccinated infants". The authors did not observe coexistence of HBsAg and anti-HBs in seven infants with persistent HBsAg. However, additional laboratory investigations including in vitro neutralization of HBsAg by polyclonal anti-HBs (HBIg, CLB) and sequence analysis of the 'a' domain revealed one arginine 145 variant in three cases that were available for investigation. 'Escape' mutants may also play a role in a low-endemic region like northwestern Europe, but the extent of the problem appears limited. Long-term immunogenicity was significantly higher in the group receiving late active immunization than in the group starting directly after birth. At the age of 5 years, the group with delayed active immunization had a significantly lower percentage (2%) of children with anti-HBs ~10 IU I-' than groups in which immunization was started at birth (15-25%). This finding is in agreement with others who found an enhancement of the immune response if the infant was older at the time of the initial injection, probably related to a more mature immune system'4.'". The implications of these findings are at present unclear. If protection against hepatitis B infection depends on the degree of immunologic priming reflected by the persistence of antibody, then a strong argument could be made for adoption of schedules that maximize anti-HBs levels. In the present study, there was a total follow-up of 186 person-years in 71 infants with anti-HBs < 10 IU I '. One infant, born to a HBeAg-negative mother, with an initial response between 10 and 100 IU I-' became HBsAg carrier after 4 years of follow-up without detectable anti-HBs. In other studies, no HBsAg positivity after 5-9 years of follow-up was found for infants with initial anti-HBs 2 10 IU 1 ', whether the infants lost their anti-HBs or not'4,'"'x. In long-term follow-up studies of immunized adults, no persistent HBsAg positivity was detected in persons with an initial anti-HBs response > 10 SRU, but transient HBsAg positivity and/or anti-HBc positivity was detected in this group, < 1% in 100 person-years exposed". At present, until more long-term follow-up studies are available, it seems advisable to aim for an initial anti-HBs response of 100 IU I-' or more for the prevention of clinically important forms of hepatitis B"'.
The confirmation of an old finding that there was no effect of the time of starting active immunization on PER facilitates the incorporation of hepatitis B vaccine into the existing Expanded Programme on Immunization (EPI) by allowing active hepatitis B vaccination concomitant with DKTP immunization. The number of visits can then be reduced as well as the number of injections if a multivalent vaccine becomes available.
